Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Ten dogs diagnosed with IMC presented to the Veterinary Teaching Hospital Complutense of Madrid were included. Diagnosis was based on clinical features (edema, erythema, warmth and firmness in the mammary glands) and histopathological confirmation. Immunohistochemical analysis (Ki-67 index, C-kit, COX-2 and androgen receptor) were performed. Five dogs received palliative treatment (antibiotics, corticoids) (control group or CG) and the other 5 dogs were treated with a combination of firocoxib, flutamide and toceranib (treatment group or TG). One dog of the TG refused treatment with toceranib due to economy matters. Survival time was defined as the time from IMC diagnosis to euthanasia or death of the dog. Age at the time of IMC diagnosis, reproductive status, previous history of mammary tumors and evolution of IMC after treatment were also analyzed. A paired Student's t-test was performed for statistical analysis of parametric variables with an alpha error of 0.05 and Chi Square test for no parametric variables.